Evidence map›Paper›PMID 39513224›Full record

ArticleFuture oncology (London, England)2024

Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study.

Lyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, Sanjay Goel, Rebecca Heist, Theresa L Werner, Keith D Eaton, Judy S Wang, Shubham Pant, Douglas R Adkins and 6 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lyudmila BazhenovaUniversity of California San Diego Moores Cancer Center, CA 92093, USA.ORCID 0000-0001-8764-4359
Dong-Wan KimSeoul National University College of Medicine & Seoul National University Hospital, Seoul, Republic of Korea.
Byoung Chul ChoYonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Sanjay GoelMontefiore Medical Center, Bronx, NY 10467, USA.
Rebecca HeistMassachusetts General Hospital, Boston, MA 02114, USA.
Theresa L WernerHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Keith D EatonUniversity of Washington & Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Judy S WangFlorida Cancer Specialists & Research Institute, Sarasota, FL 34232, USA.
Shubham PantUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Douglas R AdkinsWashington University School of Medicine in St Louis, MO 63110, USA.
Collin M BlakelyUniversity of California San Francisco, CA 94158, USA.
Xiaohong YanMirati Therapeutics Inc., San Diego, CA 92121, USA.
Saskia NeuteboomMirati Therapeutics Inc., San Diego, CA 92121, USA.
James G ChristensenMirati Therapeutics Inc., San Diego, CA 92121, USA.
Richard ChaoMirati Therapeutics Inc., San Diego, CA 92121, USA.
Todd BauerSarah Cannon Research Institute, Tennessee Oncology, Nashville, TN 37203, USA.

Funding

Mirati Therapeutics N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationTreatment OutcomeYoung Adultbasket studyMGCD516molecular alterationsitravatinibsolid tumor

Identifiers

PMID39513224
PMCPMC11654803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.